Rexahn raises $10M in registered direct offering

On June 12, cancer company Rexahn Pharmaceuticals Inc. (NYSE-M:RNN) raised $10 million through the sale of 3 million units at $3.30 in a registered direct offering. Each unit comprises a share and a ...